SEC62 and lung adenocarcinoma: The SEC62 gene is amplified in a number of cancers, including lung adenocarcinomas, prostate, thyroid and head and neck squamous cell carcinoma; accordingly it has been hypothesized that excess SEC62 may not be incorporated into SEC61 complexes and instead lead to sensitized ER‐phagy responses and, consequently, resistance to anticancer ER stress 114.